Lytix Biopharma AS will release its first half and second quarter 2021 results
on Friday, 27 August 2021 at 07.00 a.m. CEST. The results will be presented in a
webcast with CEO Øystein Rekdal and CFO Gjest Breistein at 08.00 a.m. CEST. 

The presentation and subsequent Q&A session will be held in English and may be
viewed live at https://forms.office.com/r/5WTFatrdsN 

A recording of the presentation will be made available on
https://www.lytixbiopharma.com/investors/overview.html after the presentation. 

For more information, please contact: 
Øystein Rekdal, Chief Executive Officer: +47 975 73 358 
Gjest Breistein, Chief Financial Officer: +47 952 60 512 

Lytix Biopharma in brief 
Based in Oslo, Norway, Lytix Biopharma is a clinical stage immune-oncology
company developing novel cancer immunotherapies, an area within cancer therapy
that is aimed at activating the patient's immune system to fight cancer. The
Company's technology is based on pioneering research in "host defense peptides"
- nature's first line of defense towards foreign pathogens. Lytix Biopharma's
lead product, LTX-315, is a first-in-class oncolytic peptide that has
demonstrated superior abilities to induce polyclonal t-cell responses.